Welcome Address

Dear Colleagues,

On behalf of the Royal Belgian Society of Rheumatology (KBVR-SRBR), we are pleased to announce the first-ever online edition of the Belgian Congress on Rheumatology.

This virtual congress will take place on Friday 19 March 2021.

Much to our regret it will not be possible to meet in person, but we are happy to be able to propose an interesting online programme consisting of invited talks, oral presentations and Updates in Therapeutics.

In addition to the scientific programme, a virtual exhibition and poster area will be available. There will be ample time for visiting the virtual booths, the online posters and for networking.

Together with the KBVR-SRBR board members, we hope to welcome many of you to the first virtual edition of the Belgian Congress on Rheumatology and remain,

Yours faithfully,

Peggy Jacques
Scientific President
Morning Programme

09.00 Welcome and Opening Ceremony

09.20 Keynote Lecture
From clinical trials to clinical practice: A good match?
Josef Smolen (Austria)

Young Investigators’ Meeting – Part I

09.45 Axial involvement in early peripheral spondyloarthritis: A prospective MRI study
Thomas Renson (UGent, VIB)

09.55 Immunoglobulin G antibodies to three novel peptides in early axial spondyloarthritis in two independent cohorts
Pieter Ruytinx (UHasselt)

10.05 Interleukin-23 inhibitors and their apparent ineffectiveness in the treatment of axial spondyloarthritis: A systematic review with meta-analysis
Louise Vanhoutte (KUL)

10.15 Synovial tissue histopathology findings in early RA – Is it useful?
Analysis of the Belgian CAP48 cohort
Stéphanie de Montjoye (UCL, IREC)

10.25 Coffee break and Visit of the Exhibition

Abstract Presentations

10.40 Long-term effectiveness of methotrexate with step down glucocorticoids (COBRA Slim) versus other conventional DMARD regimens as initial RA therapy: 5-year outcomes of the CareRA trial
Veerle Stouten (KUL)

10.50 Spinal magnetic resonance imaging lesions in healthy subjects compared to axial spondyloarthritis patients
Manouk de Hooge (UGent, VIB)

11.00 Should we use bioDMARDS in first intention in early Rheumatoid Arthritis? Results at 5 years from the ERA Louvain Brussels cohort
Emilie Sapart (UCL)

11.10 Patients with early rheumatoid arthritis considered to have a favourable risk profile and treated according to a step-up strategy have an increased risk of chronic analgesic consumption
Sofia Pazmino (KUL)

11.20 Novel autoantibody biomarkers for the prediction of response to first-line combination therapy in rheumatoid arthritis
Patrick Vandormael (Uhasselt)

11.30 Interplay between Treg and iNKT cells reveals a marked tissue tropism of immune regulatory networks in combined gut and joint inflammation
Koen Venken (VIB, UGent)

11.40 Update in Therapeutics – Organised with an educational grant from AbbVie
The importance of achieving remission in RA
René Marc Flipo (France)

11.55 Update in Therapeutics – Organised with an educational grant from UCB
Uveitis in axSpA
Irene van der Horst (The Netherlands)

12.10 Update in Therapeutics – Organised with an educational grant from Sanofi
Update on RA and diabetes
Philip Remans (Reumacentrum Genk)

Thieves Market

12.25 Hydroxychloroquine use not so harmless: Little reminder from a clinical case
Valérie Badot (ULB)

12.35 Treating cancer and associated “paraneoplastic” dermatomyositis with immune checkpoint inhibitor, a false good idea?
Florane Chauveheid (ULg)

12.45 Clinical case: Systemic lupus erythematosus mimicry after viral infection with Coxsackie B4
Julie Terrasson (KUL)

12.55 Lunch Break, Visit of the Exhibition and Poster Viewing
Afternoon Programme

Young Investigators’ Meeting - Part II

14.00  Laser Speckle Contrast Analysis (LASCA) in rheumatoid arthritis
       Michaël Vanden Bulcke (UGent)

14.10  The FLARE-RA questionnaire can identify OMERACT flares in
       patients with rheumatoid arthritis included in the TapERA trial
       Delphine Bertrand (KUL)

14.20  May capillaroscopy be a candidate tool in future algorithms for SSc-ILD: Are we looking for the holy grail? A systematic review
       Amber Vanhaecke (Ugent)

14.30  Epitope mapping of MDA5 using patient plasma derived
       autoantibodies
       Eveline Van Gompel (Karolinska Institute, KUL)

14.40  Update in Therapeutics – Organised with an educational grant from Galapagos
       Evolution of a JAK inhibitor: From bench to bedside
       Peter Taylor (UK)

14.55  Update in Therapeutics – Organised with an educational grant from Celltrion
       Novel opportunities with Infliximab in rheumatic diseases
       René Westhovens (KUL)

15.10  Update in Therapeutics – Organised with an educational grant from Roche
       Current and future treatments for GCA
       Daniel Blockmans (KUL)

15.25  Coffee Break and Visit of the Exhibition

15.45  Year in review - Clinical and Basic Science
       Gaelle Varkas (UGent) and Eric Gracey (VIB, UGent)

Abstract Presentations

16.15  Incidence and prevalence of systemic sclerosis associated interstitial lung disease in Flanders: A 12-years multicentre prospective cohort study
       Vanessa Smith (UGent)

16.25  Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis
       Farah Tamirou (UCL)

16.35  Serum IgG-undergalactosylation profiles reflect cumulative exposure to systemic inflammation in spondyloarthritis patients
       Ann-Sophie De Craemer (UGent, VIB)

16.45  The use of disease activity indicators for rheumatoid arthritis in Belgian daily clinical practice
       Emma Buckinx (KUL)

16.55  Unmasking the role of salivary gland involvement in anti-SSA positive patients
       Liselotte Deroo (UGent)

17.05  Systematic analysis of Covid-19 infections and symptoms in systemic lupus erythematosus population: Correlation with disease severity and treatments
       Olivier Malaise (ULg)

17.15  Keynote Lecture
       Infection prevention and vaccination strategies
       Charlotte Martin (CHU St Pierre)

17.40  Closure of the Congress and Visit of the Exhibition
Registration

<table>
<thead>
<tr>
<th>Registration Fees</th>
<th>Until 18 March</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members KBVR-SRBR</td>
<td>€ 75,00</td>
</tr>
<tr>
<td>Non Members</td>
<td>€ 95,00</td>
</tr>
<tr>
<td>Trainees in Rheumatology*</td>
<td>€ 25,00</td>
</tr>
</tbody>
</table>

* Registration as a trainee or researcher non-MD will only be accepted if accompanied by a copy of your student card or a certificate of your director (proof to be uploaded during the registration process). Without proof the non-member fee will be charged.

The registration fee for participants includes
- Participation in all scientific sessions
- Participation in the 'Updates in Therapeutics' organised by the Industry
- Access to the virtual exhibition and ePosters
- Networking opportunities on the online platform

How to register
You can register online through the congress website www.rheumacongress.be. Click on 'Registration' for details and access to the online registration form. When your registration is completed successfully, you will receive an automatic confirmation. You can also print an invoice when you finalise your online registration.

Changes/Name Substitutions
You will receive a personal link in your final confirmation email. With this link it will be possible to make changes or transfer your registration to a colleague free of charge.

Cancellations
Participants canceling their registration before 1 March 2021, will receive a 50% refund. There will be no refunds for cancellations received after this date. Cancellations must be confirmed in writing to the Organising Secretariat. All refunds will be processed after the Congress.